U.S. Expert Consensus Validates MediWound’s Chronic Wound Debridement Strategy

Event summary

  • A peer-reviewed supplement in WOUNDS titled 'Toward a Practical Framework for Debridement in Chronic Wounds' was published on April 13, 2026.
  • The consensus panel emphasizes debridement as a biologically active intervention that drives healing by reducing biofilm and bacterial burden.
  • The panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx®.
  • EscharEx® is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement of chronic and hard-to-heal wounds.
  • The global Phase III VALUE trial in venous leg ulcers (VLUs) is underway, with clinical studies in diabetic foot ulcers (DFUs) and pressure ulcers (PUs) planned for H2 2026.

The big picture

The publication of the U.S. expert consensus aligns with MediWound’s strategy for chronic wound debridement, highlighting the need for advanced therapies that deliver rapid, clinically meaningful outcomes without the burden of surgery. This consensus supports the commercial thesis for EscharEx®, positioning it as a potential new standard of care in wound management. The broader industry trend towards less invasive, biologically active interventions in chronic wound care underscores the strategic importance of MediWound’s pipeline.

What we're watching

Clinical Trial Progress
The pace at which the global Phase III VALUE trial in venous leg ulcers (VLUs) progresses and yields results will be critical for EscharEx®'s regulatory approval and commercial potential.
Market Adoption
Whether EscharEx® can gain market acceptance as a first-line debridement therapy, given its non-surgical and effective approach, will be a key factor in its success.
Regulatory Approval
The timing and outcome of regulatory filings and approvals for EscharEx® in the U.S. and other markets will significantly impact MediWound’s growth prospects.

Related topics

Biotechnology